These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1731434)

  • 1. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation.
    Schmidt-Wolf IG; Aihara M; Negrin RS; Blume KG; Chao NJ
    Transfusion; 1992 Jan; 32(1):42-5. PubMed ID: 1731434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer cell activity after cryopreservation.
    Schmidt-Wolf IG; Aihara M; Negrin RS; Blume KG; Chao NJ
    J Immunol Methods; 1989 Dec; 125(1-2):185-9. PubMed ID: 2607152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of cryopreservation on natural killer cell and lymphokine-activated killer cell activities.
    Martí F; Miralles A; Peiró M; Amill B; de Dalmases C; Piñol G; Rueda F; García J
    Transfusion; 1993 Aug; 33(8):651-5. PubMed ID: 8342231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
    Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
    Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vivo distribution of murine lymphokine activated killer cells in splenectomized host.
    Chao TY; Chu TM
    Proc Natl Sci Counc Repub China B; 1990 Dec; 14(4):223-7. PubMed ID: 2101449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes.
    Kawai H; Komiyama A; Katoh M; Yabuhara A; Miyagawa Y; Akabane T
    Transfusion; 1988; 28(6):531-5. PubMed ID: 3264091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma.
    Wang Y; Qian XJ; Hadley HR; Lau BH
    Mol Biother; 1992 Sep; 4(3):143-6. PubMed ID: 1445669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
    Yoshimori K
    Nihon Ika Daigaku Zasshi; 1992 Oct; 59(5):418-27. PubMed ID: 1430114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
    Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
    J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of B16 melanoma sublines to lymphokine-activated killer cells as determined by 51Cr-release and clonogenic assays.
    Tzeng JJ; Barth RF
    J Immunol Methods; 1990 Apr; 128(2):257-66. PubMed ID: 2324514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysis of herpes simplex virus-infected cells by lymphokine-activated killer cells.
    Chu CT; Lee P; Lin BJ; Sun MJ; Hsieh KH
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Feb; 24(1):108-18. PubMed ID: 1657543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
    Dannemann BR; Morris VA; Araujo FG; Remington JS
    J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
    Puri RK; Leland P
    Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.